In November 2024, CStone presented preclinical data for CS2009 at the 39th SITC Annual Meeting. These results show that CS2009 exhibits superior anti-tumor activity compared to potential competitors, ...

Arrivent Biopharma, Inc. (NASDAQ: AVBP) has reported its financial results for the full year 2024 and highlighted recent ...

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and ...

The presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. An archived replay will be available for at least 30 ...

Frazier Life Sciences launched Callio Therapeutics, a cancer startup headquartered in Seattle and Singapore. Frazier led ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...

A new article in the journal Nucleic Acid Therapeutics addresses the recognition by the U.S. Food and Drug Administration ...

Callio Therapeutics, a biotechnology company, has launched with the closing of a $187.0 million Series A financing round.

We were very pleased that the private placement was supported by existing investors and our Board of Directors, all of whom participated in this financing,” said Samir R. Patel, MD, President and CEO ...

Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs ...

SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026 SOTIO ...